Who are Ondansetron Oral Soluble Pellicles's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Trintellix, Ramosetron, Aprepitant, Dexamethasone, ondansetron (Zofran), Aprepitant plus Ondansetron, Ondansetron orodispersible film once, Sancuso patch.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ondansetron-oral-soluble-pellicles.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Ondansetron Oral Soluble Pellicles — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ondansetron Oral Soluble Pellicles (Ondansetron Oral Soluble Pellicles) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Serotonin 5-HT3 receptor antagonist. Area: Oncology.

phase 3 Serotonin 5-HT3 receptor antagonist 5-HT3 receptor Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Ondansetron Oral Soluble Pellicles (Ondansetron Oral Soluble Pellicles) — The First Affiliated Hospital of Xinxiang Medical College. Ondansetron works by blocking serotonin receptors in the body, which helps to reduce nausea and vomiting.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ondansetron Oral Soluble Pellicles TARGET	Ondansetron Oral Soluble Pellicles	The First Affiliated Hospital of Xinxiang Medical College	phase 3	Serotonin 5-HT3 receptor antagonist	5-HT3 receptor
Trintellix	vortioxetine	Takeda	marketed	Serotonin modulator and stimulator (SMS); SSRI-like agent	Serotonin transporter (SERT); 5-HT3 receptor; 5-HT1A receptor	2013-01-01
Ramosetron, Aprepitant, Dexamethasone	Ramosetron, Aprepitant, Dexamethasone	Hallym University Medical Center	marketed	5-HT3 antagonist / NK1 antagonist / corticosteroid combination	5-HT3 receptor, NK1 receptor, glucocorticoid receptor
ondansetron (Zofran)	ondansetron (Zofran)	National Institute on Alcohol Abuse and Alcoholism (NIAAA)	marketed	5-HT3 receptor antagonist	5-HT3 receptor
Aprepitant plus Ondansetron	Aprepitant plus Ondansetron	University of Pittsburgh	marketed	NK1 receptor antagonist + 5-HT3 receptor antagonist combination	NK1 receptor (aprepitant); 5-HT3 receptor (ondansetron)
Ondansetron orodispersible film once	Ondansetron orodispersible film once	Chongqing University Cancer Hospital	marketed	5-HT3 receptor antagonist	5-HT3 receptor
Sancuso patch	Sancuso patch	LG Life Sciences	marketed	5-HT3 receptor antagonist	5-HT3 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Serotonin 5-HT3 receptor antagonist class)

CCTU · 1 drug in this class
GlaxoSmithKline · 1 drug in this class
RedHill Biopharma Limited · 1 drug in this class
The First Affiliated Hospital of Xinxiang Medical College · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ondansetron Oral Soluble Pellicles — Competitive Intelligence Brief. https://druglandscape.com/ci/ondansetron-oral-soluble-pellicles. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab